Respiratory Distress Syndrome (RDS)

  • Martha D. Mullett

Abstract

Premature infants have been known to die from pulmonary failure for many years. In the 1950s this cause of mortality in the neonatal period was treated supportively with temperature regulation, oxygen, and antibiotics. In the early 1960s it was determined that pulmonary failure was caused by lack of a surface active substance in the lung [1]. This substance was named pulmonary surfactant, and the clinical disorder was named respiratory distress syndrome (RDS). The pathologic description of the disorder led to the name ‘‘hyaline membrane disease” [2]. Therapies encompassing more specific measures, such as continuous positive airway pressure, ventilatory support, nutrition, and medications such as sodium bicarbonate, were devised to improve survival in infants with RDS [3,4]. Even with the utilization of these measures, RDS was still the major factor contributing to death in 11,900 infants per year in the years 1969 to 1973. The average contribution of RDS to the neonatal mortality rate—20%— made it the highest single factor associated with death in neonates [5].

Keywords

Cholesterol Surfactant Ischemia Respiration Bicarbonate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Avery ME, Mead J: Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 97:517–523, 1959.Google Scholar
  2. 2.
    Potter EL: Pulmonary pathology in the newborn. Adv Pediatr 6:157–189, 1953.PubMedGoogle Scholar
  3. 3.
    Gregory GA, Kitterman JA, Phibbs RH, et al: Treatment of idiopathic respiratory distress syndrome with continuous positive airway pressure. N Engl J Med 284:1333–1340, 1971.PubMedCrossRefGoogle Scholar
  4. 4.
    Usher RH: Reduction of mortality from respiratory distress syndrome of prematurity with early administration of intravenous glucose and bicarbonate. Pediatrics 32:966–975, 1963.PubMedGoogle Scholar
  5. 5.
    Ferrell PM, Wood RE: Epidemiology of hyaline membrane disease in the United States: Analysis of national mortality statistics. Pediatrics 58:167–176, 1976.Google Scholar
  6. 6.
    Liggans GC, Howie RN: A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 50:515–525, 1972.Google Scholar
  7. 7.
    Collaborative Group on Antenatal Steroid Therapy: Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. Am J Obstet Gynecol 141:276–286, 1981.Google Scholar
  8. 8.
    Herron MA, Katz M, Creasy RK: Evaluation of a preterm birth prevention program: Preliminary report. Obstet Gynecol 59:452–456, 1982.PubMedGoogle Scholar
  9. 9.
    Goerke J: Lung surfactant. Biochem Biophys Acta 344:241–261, 1974.PubMedGoogle Scholar
  10. 10.
    Possmayer F, Yu SH, Weber JM, et al: Pulmonary surfactant. Can J Biochem Cell Biol 62:1121–1133, 1984.PubMedCrossRefGoogle Scholar
  11. 11.
    Notter RH, Finkelstein JN: Pulmonary surfactant: An interdisciplinary approach. J Appl Physiol: Respir Environ Exer Physiol 57(6): 1613–1624, 1984.Google Scholar
  12. 12.
    Sanders RL: Lung development: Biological and clinical perspectives. In Ferrell PM (Ed): New York: Academic Press, 1982, pp. 192–210.Google Scholar
  13. 13.
    Shapiro DL, Notter RH, Morin FC, et al: Double-blind, randomized trial of calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 76:594–599, 1985.Google Scholar
  14. 14.
    Chu J, Clements JA, Cotton EK, et al: Neonatal pulmonary ischemia: Clinical and physiological studies. Pediatrics 40:709–782, 1967.PubMedGoogle Scholar
  15. 15.
    Robillard E, Dagenais-Perusse AY, et al: Microaerosol administration of synthetic beta-gamma-dipalmitoyl L lecithin in the respiratory distress syndrome: A preliminary report. Can Med Assoc J 90:55–57, 1964.PubMedGoogle Scholar
  16. 16.
    Hagwood S, Schlueter MA, Brown CL, et al: Effects of phospholipids (PL), recombinant human surfactant glycoprotein (SP28–36) and human surfactant proteins (SP5, SP18) on the pulmonary mechanics of premature rabbits. Pediatr Res 21(4):454A, 1987.Google Scholar
  17. 17.
    Nogee LM, Rice WR, Whitsett JA: Role of distinct pools of surfactant protein (SAP-35) in regulation of surfactant secretion. Pediatr Res 21(4):461 A, 1987.Google Scholar
  18. 18.
    Glasser SW, Korfhagen TR, Weaver LTE: Cloning and predicted structure of hydrophobic surfactant protein SPL (Phe). Pediatr Res 21(4):361 A, 1987.Google Scholar
  19. 19.
    Snyder JM, Rodgers HR, O’Brian JA, et al: Uptake of the major surfactant aproprotein by neonatal lung tissue. Pediatr Res 21(4):222A, 1987.CrossRefGoogle Scholar
  20. 20.
    Ballard PL, Hawgood S, Wellenstein GA, et al: Surfactant protein of 18,000 dalton (SP 18) in human fetal lung. Pediatr Res 21(4):442A, 1987.Google Scholar
  21. 21.
    Wilkinson A, Jenkins PA, Jeffrey JA: Two controlled trials of dry artificial surfactant: Early effects and later outcome in babies with surfactant deficiency. Lancet 2:287–291, 1985.PubMedCrossRefGoogle Scholar
  22. 22.
    Milner AD, Vyas H, Hopkins IE: Effect of exogenous surfactant on total respiratory system compliance. Arch Dis Child 59:369–371, 1984.PubMedCrossRefGoogle Scholar
  23. 23.
    Morley CJ, Bangham AD, Miller N: Dry artificial lung surfactant and its effect on very premature babies. Lancet 1:64–68, 1981.PubMedCrossRefGoogle Scholar
  24. 24.
    Halliday HL, McClure G, McReid M, et al: Controlled trial of artificial surfactant to prevent respiratory distress syndrome. Lancet 1:476–478, 1984.PubMedCrossRefGoogle Scholar
  25. 25.
    Hallman M, Merritt TA, Schneider H, et al: Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. Pediatrics 71:473–482, 1983.PubMedGoogle Scholar
  26. 26.
    Merritt TA, Hailman M, Bloom BT, et al: Prophylactic treatment of very premature infants with human surfactant. N Engl J Med 315:785–790, 1986.PubMedCrossRefGoogle Scholar
  27. 27.
    Hallman M, Merritt TA, Jarvenpaa AL: Exogenous human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trial. J Pediatr 106:963–969, 1985.PubMedCrossRefGoogle Scholar
  28. 28.
    Fujiwara T, Meata H, Chica S, et al: Artificial surfactant therapy in hyaline membrane disease. Lancet 1:55–59, 1980.PubMedCrossRefGoogle Scholar
  29. 29.
    Fujiwara T: Surfactant replacement in neonatal RDS. In Robertson B, VanGolde LMG, Batenburg JJ (Eds): Pulmonary Surfactant. Amsterdam: Elsevier Science Publishers, 1984, pp. 479–503.Google Scholar
  30. 30.
    Kwong MS, Egan E, Notter RH, et al: Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. Pediatrics 76:585–592, 1985.PubMedGoogle Scholar
  31. 31.
    Enhorning G, Shennan A, Possmayer F, et al: Prevention of neonatal respiratory distress syndrome by tracheal installation of surfactant: A randomized clinical trial. Pediatrics 76(2): 145–152, 1985.PubMedGoogle Scholar
  32. 32.
    Gitlin JD, Soll RF, Parad RB, et al: Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease. Pediatrics 79(1):31–37, 1987.PubMedGoogle Scholar
  33. 33.
    Halliday HL, McClure G, Reid M: Growth and development two years after artificial surfactant replacement at birth. Early Hum Devel 13:323–327, 1986.CrossRefGoogle Scholar
  34. 34.
    Dunn MS, Shennan AT, Hoskins EM, et al: Two year follow-up of infants enrolled in a randomized trial of surfactant supplementation. Pediatr Res 21(4):359A, 1987.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • Martha D. Mullett

There are no affiliations available

Personalised recommendations